• SU 5402: What the Product Record Supports

  2026-10-16

  A source-limited overview of SU 5402 identity, reported receptor-tyrosine-kinase activity, downstream readouts, and the boundaries of evidence available from the APExBIO product description.

• Saracatinib (AZD0530): Mechanism and Evidence Scope

  2026-10-16

  Saracatinib (AZD0530) is described by APExBIO as a dual Src-family kinase and Abl inhibitor, with reported biochemical activity against c-Src and v-Abl and broader activity across several Src-family members. The available material supports a cautious mechanistic framework linking Src-pathway suppression with cell-cycle, motility, and xenograft readouts, but it does not provide an identity-matched primary paper, effect sizes, sample sizes, or independent validation.

• Nocodazole and Spiroplasma Cell Entry

  2026-10-15

  Wei et al. used Drosophila Schneider 2 cells to examine how Spiroplasma eriocheiris enters invertebrate host cells. Their inhibitor-based evidence implicated clathrin-mediated endocytosis, macropinocytosis, actin filaments, and microtubules, while also showing substantial infection-associated cytotoxicity. Nocodazole was informative as a microtubule perturbation tool, but its effects do not by themselves establish a direct entry mechanism or predict infection in crustacean tissues.

• Cy3 NHS Ester: Identity, Mechanism and Evidence

  2026-10-15

  APExBIO describes Cy3 NHS ester (non-sulfonated) as an amino-reactive cyanine fluorophore with orange-region emission. The available evidence supports a documented product identity, chemical labeling principle, and optical measurement scope, but provides no identity-matched study establishing labeling efficiency, comparative performance, or biological outcomes.

• Cy3 NHS Ester: Identity, Mechanism and Evidence Scope

  2026-10-14

  Cy3 NHS ester (non-sulfonated), identified by APExBIO as SKU A8100, is a non-sulfonated cyanine fluorescent reagent described for amino-group labeling of proteins, peptides, oligonucleotides, and DNA. Its reported optical values support interpretation as an orange-emitting fluorescence reporter, but the available product information does not establish labeling efficiency, site selectivity, biological compatibility, or performance in a matched research study.

• Cy3 NHS Ester: Identity and Evidence Scope

  2026-10-14

  Cy3 NHS ester (non-sulfonated), APExBIO SKU A8100, is described by its supplier as a fluorescent labeling reagent for amino-containing biomolecules. The available evidence is limited to product documentation; no matched peer-reviewed paper was provided, so performance, reproducibility, and application-specific benefits cannot be independently assessed.

• Baicalein: Evidence Boundaries in Cell Research

  2026-10-13

  Baicalein, or 5,6,7-trihydroxy-2-phenylchromen-4-one, is presented by APExBIO as a flavonoid research compound associated with studies of arachidonic acid metabolism, inflammation, apoptosis and cancer biology. The supplied NeuroToxicology study concerns formononetin—not baicalein—and therefore provides contextual evidence about chemotherapy-induced neurotoxicity rather than direct evidence for baicalein’s effects.

• SMYD2 Inhibition in Cisplatin-Related Renal Fibrosis

  2026-10-12

  A 2023 study investigated whether SMYD2 contributes to cisplatin-induced chronic kidney injury and whether pharmacological inhibition is associated with reduced fibrosis and inflammation. The findings support SMYD2 as a candidate regulator in this model, but they do not establish clinical efficacy, mechanism-specific causality, or applicability to chronic kidney disease broadly.

• Baicalein Research Context and Evidence Limits

  2026-10-12

  Baicalein, also known as 5,6,7-trihydroxy-2-phenylchromen-4-one, is described by APExBIO as a research compound relevant to arachidonic acid metabolism, cancer biology, apoptosis, and inflammation. A separate 2026 study of formononetin provides context for evaluating neuroprotection claims, but it did not test Baicalein and does not establish comparable effects for this compound.

• AIBP–LRP2 Signaling in Collateral Circulation

  2026-10-10

  Zhu et al. identify an AIBP–LRP2–HDL–miR-223 pathway that limits the expansion of CXCR4-positive, stemlike capillary endothelial cells during ischemic collateral remodeling. The study proposes a two-phase model in which capillary endothelial cells first expand and then acquire arterial characteristics, while also defining the limits of translating this preclinical mechanism to human peripheral artery disease.

• Baicalein: Evidence, Applications, and Limitations

  2026-10-09

  Baicalein, or 5,6,7-trihydroxy-2-phenylchromen-4-one, is a flavonoid research compound associated with 12-lipoxygenase, cancer biology, apoptosis, and inflammation studies. This overview separates supplier-described properties from published findings, explains its conceptual research applications, and emphasizes that the supplied evidence does not establish clinical efficacy or confirm baicalein as a neuroprotective treatment.

• Dlin-MC3-DMA in RNA Delivery: Evidence and Limits

  2026-10-09

  Dlin-MC3-DMA is widely discussed as an ionizable cationic liposome lipid for nucleic-acid delivery, but its established role should be separated from broader lipid nanoparticle claims. This overview examines the research context, conceptual applications, and evidence boundaries using the 2025 study by Rafiei, Shojaei, and Chau, which applied machine learning to mRNA lipid nanoparticles designed to modulate inflammatory microglia. The study supports cell-state-aware formulation research, while leaving important questions about Dlin-MC3-DMA-specific performance, in vivo translation, biodistribution, safety, and therapeutic efficacy unresolved.

• Carvedilol Phosphate: Interpreting Hepatic IRI

  2026-10-08

  Carvedilol Phosphate offers a useful pharmacological lens for studying adrenergic signaling without being mistaken for a validated hepatic IRI treatment. This evidence-focused review connects the compound’s research role with the Arrb2–6-ketoLCA–macrophage axis and defines the boundaries of interpretation.

• Cy3 NHS Ester (Non-Sulfonated) Overview

  2026-10-08

  Cy3 NHS ester (non-sulfonated), SKU A8100, is a supplier-described orange fluorescent dye for conceptual amino-group labeling of proteins, peptides, and oligonucleotides. No matched peer-reviewed paper evidence was provided, so application performance remains unverified.

• SB 202190 in p38 MAPK Research: Evidence and Limits

  2026-10-07

  SB 202190 is a widely used research compound described as a cell-permeable p38α/β inhibitor, but its interpretation requires separating supplier-reported biochemical properties from independent biological evidence. A 2024 PLOS Biology study connects p38β/MAPK11 signaling with extracellular-matrix internalization and invasive cancer-cell migration, while also showing why pharmacological results should not be treated as isoform-specific or therapeutic proof.

7995 records 1/533 page Next 12345 下5页 Last page